Regrow Biosciences gets USFDA Nod for Phase II trials of ‘OSSGROW’ for Osteonecrosis in the US
3 min read
The National Reader
OSSGROW is India’s first FDA (DCGI) approved product that has treated over 1000 patients across 200 hospitals...